Leap-015: Lenvatinib + Pembrolizumab + Mfolfox6 In Advanced/Met Gastroesophageal Adenocarcinoma

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

ASCO GI: Adding Lenvatinib to Pembrolizumab in Patients With Advanced Gastric Cancer

Bemarituzumab + mFOLFOX6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma

Promising results from the gastric cancer cohort of LEAP-005

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

Genomic landscape of late-stage gastric cancer treated with pembrolizumab

Pembrolizumab in Advanced Gastric Cancer Treatment

Targeted Oncology

KEYNOTE-062: pembrolizumab vs. chemo in 1L advanced gastric cancer

Perioperative pembrolizumab for stomach cancer treatment

RiME: nivolumab, rucaparib and ramucirumab in advanced gastroesophageal cancer

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

Gastroesophageal Cancer: Current Positioning of Immunotherapy

Pembrolizumab plus chemotherapy for esophageal cancer: KEYNOTE-590

KEYNOTE-859: pembrolizumab plus chemotherapy in G/GEJ adenocarcinoma

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric...

Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric Cancer

Targeted Oncology

Pembrolizumab Alone or With Chemotherapy for Advanced Gastric/GE Junction Cancer

Pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancer

Dr. Svensson on PD-1/PD-L1 Status in Esophageal and Gastric Adenocarcinoma